Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 4 March 24, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average burden hours per

Form 5 obligations may continue. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

response... 0.5

See Instruction

30(h) of the Investment Company Act of 1940

1(b).

Stock

Stock

Common

(Print or Type Responses)

1. Name and Address of Reporting Person ** WACHTER ERIC PHD			2. Issuer Name and Ticker or Trading Symbol PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last)	(First) (I		3. Date of Earliest Transaction				_X_ Officer (give below)	below)	er (specify		
			(Month/Day/Year) 03/20/2014					Chief Technology Officer			
(Street) 4. If Ame				endment, Date Original				6. Individual or Joint/Group Filing(Check			
KNOXVIL	Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table I - No	n-D	erivative Se	curiti	ies Acqu	iired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deemed Execution D any (Month/Day	Date, if Transa Code	8)	4. Securitie on(A) or Disp (Instr. 3, 4 a	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/20/2014		M		25,000	A	\$ 0.95	5,418,236	D		
Common Stock	03/20/2014		M		14,248	A	\$ 0.75	5,432,484	D		
Common Stock	03/20/2014		M		600,000	A	\$ 0.93	6,032,484	D		

0.93

4,867

I

By Trust

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of tionDerivative Securities (a) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun Numbe Shares
Employee Stock Option (Right to buy)	\$ 0.95	03/20/2014		M		25,000	05/27/2004	05/27/2014	Common Stock	25,00
Employee Stock Option (Right to buy)	\$ 0.75	03/20/2014		M		14,248	05/25/2005	05/25/2015	Common Stock	14,24
Employee Stock Option (Right to buy)	\$ 0.93	03/20/2014		M		600,000	09/06/2011	09/06/2021	Common Stock	600,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
WACHTER ERIC PHD			Chief				
7327 OAK RIDGE HIGHWAY, SUITE A			Technology				
KNOXVILLE, TN 37931			Officer				

Signatures

Reporting Person

/s/ Eric Wachter	03/24/2014		
PHD	03/24/2014		
**Signature of	Date		

Reporting Owners 2

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.